What is ARS Pharma?
ARS Pharma, established in 2015 and headquartered in San Diego, California, is a pharmaceutical company dedicated to developing innovative solutions for severe allergic reactions. Their flagship product is an intranasal epinephrine spray, engineered with a proprietary absorption technology designed for rapid intervention in cases of anaphylaxis triggered by food, medications, or insect bites. The company's focus on this critical unmet medical need positions it as a key player in the emergency medicine and allergy treatment landscape.
How much funding has ARS Pharma raised?
ARS Pharma has raised a total of $75M across 2 funding rounds:
Series C
$20M
Series D
$55M
Series C (2018): $20M with participation from Deerfield
Series D (2021): $55M led by SR One, RA Capital Management, and Deerfield
Key Investors in ARS Pharma
Deerfield
Deerfield Management is an investment firm focused on advancing healthcare through investment, intelligence, and philanthropy, supporting companies across the healthcare ecosystem with flexible funding models and driving innovation using AI, data, and market research.
SR One
SR One is a venture capital firm that invests in early-stage drug discovery and development companies, providing crucial capital and strategic guidance to advance novel therapeutics.
RA Capital Management
RA Capital Management is a healthcare-focused investment firm that provides capital to companies developing innovative therapies and medical technologies, actively supporting portfolio companies through their growth stages.
What's next for ARS Pharma?
The recent major strategic investment in ARS Pharma signals a pivotal growth phase, likely enabling the company to accelerate its product development pipeline, scale manufacturing capabilities, and expand its market reach. This significant backing, particularly from specialized healthcare investors, suggests a strong confidence in ARS Pharma's technology and its potential to capture a substantial share of the emergency allergy treatment market. The company is poised to advance its mission of providing life-saving solutions to patients experiencing severe allergic reactions.
See full ARS Pharma company page
